# Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II

> **NCT05909488** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **PT. Prodia Stem Cell Indonesia** · enrollment: 30 (estimated)

## Conditions studied

- Retinitis Pigmentosa

## Interventions

- **BIOLOGICAL:** 1.5 x 10^6 UC-MSC + CM
- **BIOLOGICAL:** 5 x 10^6 UC-MSC + CM

## Key facts

- **NCT ID:** NCT05909488
- **Lead sponsor:** PT. Prodia Stem Cell Indonesia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-07
- **Final completion:** 2027-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05909488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05909488, "Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05909488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*